M&A

News

Gilead has agreed to buy Ouro and its T-cell engagers for autoimmune diseases in a $2.2bn deal that may also revive its alliance with Galapagos.

News

Novartis has agreed to buy a PI3Kα-targeting drug for breast cancer from Synnovation, a potential successor to its Piqray brand, for $2bn upfront.

News

Veeva Systems has reached a $100m deal to acquire Ostro, which helps pharma connect with doctors and patients using AI-based conversational tools.

R&D

January and February this year weren't a story of a few dominant megadeals, but rather a dense constellation of cross‑disciplinary alliances.

News

Servier has made a takeover offer for Day One and its fast-growing glioma therapy Ojemda, as it pitches to drive sales above €10bn by 2030.

News

Atrium Therapeutics has launched with $270m in funding and two preclinical siRNA candidates for rare genetic cardiomyopathies.